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There is an alarming increase in the number of cases of diabetes with the global prevalence rate at 9%
for the year 2014 (1). Around 387 million patients worldwide are suffering from diabetes, and this
number is expected to increase by 50% by 2030 (2). In particular, the South East Asian countries
are affected most due to diabetes with projected 10% increase in diabetic patients by 2035 (3).
Diabetes is strongly associated withmicrovascular complications andwith the rise in the numbers of
people with diabetes, there is a precipitous increase in patients suffering from diabeticmicrovascular
complications (4, 5). Most of the microvascular beds are affected in diabetes but those in the kidney,
retina, and myelinated nerves get affected the most. In diabetes, there is a constant demand of new
cells to “replace” the dying endothelium and to keep the microvasculature healthy in order to meet
the physiological demands of respective tissues (5). However, metabolic perturbations of diabetes
fail tomaintain the burgeoning demand of dying endothelium creating widespread areas of ischemia
and underperfusion. While the pharmaceutical development of anti-diabetic medications is mainly
centered on controlling hyperglycemia, there is an apparent lack of therapies which specifically are
focused on promoting the endogenous repair of the vasculature. Studies over the past several years
highlight that cell-based therapies involving adult stem and progenitor cells hold promise of rescuing
the dying endothelium in diabetes. This novel therapeutic strategy involves stem cells obtained
from a variety of sources, such as circulating endothelial progenitor cells, mesenchymal stromal
cells (MSCs), embryonic stem cells, and inducible pluripotent stem cells (iPSCs). This research
topic discussed therapeutic potential and recent developments in cells therapies for the treatment of
diabetic microvascular complications.
Mesenchymal stromal cells are at a forefront of the cell-based therapies and Davey et al. elegantly
summarized importance of MSCs for diabetic microvascular complications (6). The review article
suggests that MSCs play a critical role in the treatment of microvascular complications due to
the multipotency and paracrine mechanisms of MSCs. The treatment of MSCs is reported to
help in maintaining glycemic control by differentiation of MSCs into insulin-producing cells (7).
MSC injection in animal model of spinal cord injury results in local upregulation of neurotrophic
factors, such as nerve growth factor (NGF), and restoration of nerve conduction velocity (8). Using
an animal model of diabetic nephropathy, previous studies have shown engraftment of 11% of
MSCs into the kidneys of diabetic animals. MSC treatment resulted in a decrease in mesangial
thickening and macrophage infiltration, thus helping to correct kidney dysfunction in diabetes (9).
In addition to diabetic microvascular complications, the MSCs are also shown to be beneficial in
the treatment of diabetic wound healing (10), cardiomyopathy (11), and bone-fracture (12). It is
noteworthy that there are about 14 open clinical trials usingMSCs to treat the diabetes and associated
complications.
Dr. Rajashekhar further reiterated the importance of MSCs in diabetic microvascular com-
plications in his review by summarizing the critical benefits of MSCs for the treatment
of diabetic retinopathy (13). His article suggests that MSCs derived from adipose tissues
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[i.e., adipose-derived stem cells (ASCs)] possess similarities with
pericytes. Retinal pericytes provide necessary support for the
retinal vasculature. Diabetic retinopathy is associated with the
loss of pericytes (14). His studies suggest that ASCs help in the
treatment of injured retina either by paracrine repair or by physical
proximity with the endothelial cells (15). Adipose tissue is the
primary source of ASCs which provides an advantage of ease of
isolation and abundance as compared to bone marrow.
Furthermore,Mizukami andYagihashi summarized the impor-
tance of ASCs in the treatment of diabetic neuropathy (16)
adding to Dr. Rajashekhar’s research on diabetic retinopa-
thy. Their review suggests that ASC treatment releases neu-
rotrophic factors such as epidermal growth factor, transforming
growth factor-β1 (TGF-β1) (17), vascular endothelial growth fac-
tor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte
growth factor, insulin like growth factor 1 (IGF-I), and brain-
derived neurotrophic factor (BDNF) while exhibiting a repar-
ative function in diabetic neuropathy (18). In addition to the
release of growth factors, the ASCs also differentiate into tar-
get organ in small percentage and possess immunosuppressive
effects (19).
Adding to the novel stem cell therapies for diabetic microvas-
cular complications, Lois et al. summarized the importance of
endothelial cell forming cells (ECFCs) in diabetic retinopathy
(20). Their studies suggest that ECFCs possess a remarkably high
proliferative capacity and tend to integrate intomature endothelial
cells (21). These ECFCs when injected in vivo home to ischemic
retina and integrate into retinal vasculature (22).
While stem cell treatments for diabetic mircrovascular compli-
cations are promising, diabetes leads to defects in their normal
reparative function. Our studies suggest that diabetes results in
dysfunction of CD34+ cell (23) of diabetic patients. Diabetic
CD34+ cells show decrease inmigration, proliferation, and incor-
poration (24) in blood vessels. We characterized that defects in
diabetic CD34+ cells are observed due to decrease in nitric oxide
(NO) levels and restoration of NO helps in correcting CD34
dysfunction (23). We used a variety of pharmacological agents
like TGF-β1 morpholino (25), angiotensin 1-7 (Ang 1-7) (26)
to correct low levels of NO and restore the functional ability of
diabetic CD34+ cells.
In the era of regenerative medicine, stem cell treatments for
diabetic microvascular complications hold a significant potential;
however, there are series of challenges to overcome such as (i)
choice of an ideal stem cell type, (ii) rigorous characterization of
stem cells, (iii) site of injection and route of delivery, (iv) limited
survival, (v) risk of tumors, and (vi) impaired potency, before the
cell therapy reaches to the clinic. However, with advancement in
research, stem cells will provide effective treatments for diabetic
microvascular complications.
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